Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22896355 | 0.91 | L3MBTL1 (0.56) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL30133620 | 0.91 | L3MBTL1 (0.56) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL22897241 | 0.86 | SMN1; SMN2 (0.57) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL22897262 | 0.85 | ALDH1A1 (0.60) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL22897182 | 0.85 | CAPN1 (0.46) | L3MBTL1GAACAPN1 | |
| SCHEMBL22896801 | 0.84 | CAPN1 (0.48) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL22897034 | 0.83 | CAPN1 (0.49) | L3MBTL1KMT2AMEN1GAACAPN1 | |
| SCHEMBL22897186 | 0.82 | CAPN1 (0.51) | CAPN1 | |
| SCHEMBL22897206 | 0.81 | HPGDS (0.50) | L3MBTL1KMT2AMEN1CAPN1ALDH1A1 | |
| SCHEMBL22897165 | 0.81 | CAPN1 (0.52) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | L3MBTL1 3522/4885KMT2A 4418/4885MEN1 4845/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | L3MBTL1 4453/4885KMT2A 4469/4885MEN1 4832/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | L3MBTL1 3522/4885KMT2A 4418/4885MEN1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.